米格列奈钙对2型糖尿病患者尿白蛋白及游离脂肪酸的影响

Effects of mitiglinide on urinary albumin and free fatty acid in 30 patients with type 2 diabetes mellitus

目的评价米格列奈钙对2型糖尿病(T2DM)患者尿白蛋白(Alb)及游离脂肪酸(FFA)的影响。方法 30例T2DM患者口服米格列奈钙30mg/d,分别检测治疗前、治疗后3、6、12个月的空腹血糖、餐后30-min及60-min血糖、空腹血浆胰岛素、糖化血红蛋白、尿Alb、空腹血脂、空腹及餐后60-min FFA。结果与治疗前比较,米格列奈钙治疗3、6、12个月后,空腹血糖、餐后血糖和糖化血红蛋白逐渐降低(P<0.05)。与治疗前比较,米格列奈钙治疗12个月后,尿Alb和60-minFFA明显降低[(28.80±3.31)mg/L vs.(20.67±1.39)mg/L和(0.53±0.04)mmol/L vs.(0.31±0.03)mmol/L](P<0.05)。结论米格列奈钙不仅可以有效降低血糖,而且可以降低尿Alb及改善脂代谢。

Objective To investigate the effects of mitiglinide on urinary albumin（Alb）and free fatty acid（FFA）in 30patients with type 2diabetes mellitus（T2DM）treated with mitiglinide 30mg/d.Methods Mitiglinide was divided into three doses given just before each meal and the treatment lasted for 12months.Blood glucose and immunoreactive insulin were measured before and in the 3rd,6th and 12th month during treatment.The parameters related to glucose and lipid metabolism and urinary Alb were determined.Results Compared to before,blood glucose and glycosylated hemoglobin were significantly decreased in the 3rd,6th and 12th month during treatment（P〈0.05）.After treatment with mitiglinide for 12months,plasma FFA significantly decreased[（0.53±0.04）mmol/L vs.0.31± 0.03）mmol/L]（P〈0.05）.So did the urinary Alb[（28.80±3.31）mg/L vs.（20.67±1.39）mg/L]（P〈0.05）.Conclusion Mitiglinide is effective in reducing blood glucose and urinary Alb in the patients with T2DM.